Peptide dosing reference

The largest 24-week programme failed to show significant weight loss versus placebo; oral trial dosing should not be used as proof for SC community protocols.

1/4/8 mg daily human arms are documented. Longer cycles are much less established.

This belongs in a topical concentration table, not an injectable peptide-dose table.

Human studies use different routes and much larger absolute amounts. They do NOT validate the familiar 250–500 mcg SC protocol.

Evidence for BPC and full-length thymosin-β4 does not establish efficacy, compatibility or safety of the combined SC protocol.

There is no single Phase-2 ladder: lower arms were fixed while higher arms escalated. Show the arms separately.

Cerebrolysin has substantial human dosing literature and official product guidance in countries where used; it is not FDA-approved in the US.

The original human CJC-1295 data are for long-acting DAC CJC-1295. Do not use those PK data to validate no-DAC schedules.

Several incompatible community conventions exist. Display them side-by-side rather than inventing one 'standard'.

Human trials used IV weight-based dosing, not SC bedtime microgram protocols. The insomnia trial found only weak effects and concluded major therapeutic benefit was unlikely.

The 48-week Phase 2 trial is unusually useful because it directly compared fixed and escalating schedules. Keep all six schedules rather than reducing them to '1–9 mg weekly'.

Older Russian bioregulator literature is often cited imprecisely and sometimes mixes Epitalon with Epithalamin. PP should not label 5–10 mg/day as a proven human clinical dose unless the original human paper is recovered and verified.

The evidence for topical GHK-Cu cannot be used to validate systemic injection. Modern reviews explicitly describe the human clinical literature as thin and fragmented.

The community's repeated SC boluses are not the same regimen as the strongest chronic human study, which used continuous weight-based infusion. A 5-day human SC study also found attenuation of the GH response.

The published human PK doses are extraordinarily larger, weight-based IV exposures and should not be presented as support for 100–300 mcg SC community use.

GLOW is a fixed-ratio commercial blend, not a clinically studied molecule. Different sites even use different protocol logic, so PP should show the component amounts delivered by every total-blend dose.

Human ipamorelin data demonstrate acute GH pharmacology, not the efficacy or safety of chronic 100–300 mcg SC community protocols.

Kisspeptin-10 has clear acute human dose-response data, but essentially no evidence validating repeated community SC schedules. Reproductive state and sex materially change response.

KLOW protocols disagree substantially. Because the vial is fixed at 50:10:10:10, PP should always display both total blend and each component amount. No human trial validates the combination.

KPV is a good example where PP should resist false precision: preclinical concentrations do not translate into a human dose, and retail/community figures have no completed human dose-finding trial behind them.

Human evidence is TOPICAL wound treatment. It does not establish a systemic injectable dose; PP should show concentration, volume per wound area and active µg/cm² separately.

Mazdutide now has materially broader human dose data than the old 3–6 mg summary. The 10 and 16 mg US groups should be represented as trial arms, not as community targets.

The administered human dose is unknown. Online 5–10 mg schedules are community/clinic conventions, not clinical-trial doses. PP should say this prominently.

Human Phase-I dosing was weight-based and produced nausea, fatigue and erections. Modern fixed-dose tanning protocols are unapproved community practice.

NAD+ is a coenzyme, not a peptide. The 750 mg human pilot is useful pharmacology evidence but does not validate the very broad IV/SC wellness protocols.

Do not merge licensed obstetric IV/IM dosing with intranasal social/behavioral protocols. They are different routes, indications and exposure patterns.

This is a weak-evidence entry. PP should explicitly say that the familiar 5–10 mg human course is convention rather than a dose established by controlled human trials.

The licensed 1.75 mg regimen has explicit frequency and cardiovascular/hyperpigmentation warnings. Male and postmenopausal use is off-label and should not be presented as licensed.

Retatrutide remains investigational despite Phase-3 publication. Phase 2 showed GI events concentrated during escalation and partly mitigated by the lower 2 mg starting dose.

Selank is a good candidate for PP's 'source transparency' model: one human dose is unusually specific, while much of the online 100–600 mcg advice is community convention rather than a clearly documented clinical regimen.

Semaglutide has strong licensed and Phase-3 dosing evidence. PP should distinguish Wegovy obesity dosing from Ozempic diabetes dosing and should not call community 'microdosing' an evidence-based regimen.

Semax dosing is indication- and formulation-dependent. Acute Russian neurological protocols can be many times larger than Western nootropic schedules, so PP should not collapse them into a single 200–600 mcg figure.

Modern 200–600 mcg bedtime schedules are compounded-clinic conventions, not a continuation of a currently licensed US product. Historical weight-based dosing and modern wellness dosing should remain separate.

SLU-PP-332 is NOT a peptide; it is a small-molecule ERR agonist. There is no human dose, no human pharmacokinetics and no human safety dataset. Any human schedule on the internet is speculative and should receive PP's lowest evidence grade.

SNAP-8 should never be displayed like an injectable peptide. PP needs a topical-only table explaining the difference between percentage of commercial solution and actual active acetyl-octapeptide concentration.

This entry changed materially in 2025: elamipretide is now an FDA-approved medicine (Forzinity) for Barth syndrome patients ≥30 kg. Research-vial 'SS-31' community schedules remain unapproved and should not borrow the product's efficacy/safety claims.

TB-500 sold online is generally described as a fragment/analogue and is not interchangeable with full-length thymosin-β4 used in human IV studies. PP must not cite full-length Tβ4 trials as proof that mg-level SC TB-500 works.

Tesamorelin is a strong example of why 'units' should never be shown without mg and concentration: Perfect B's 25 units = 1 mg only because its example uses 10 mg in 2.5 mL. PP should always make milligrams the primary dose.

Unlike many compounds on PP, thymalfasin has substantial human dosing experience, but approvals and indications vary by country. The familiar 1.6 mg twice-weekly schedule has genuine clinical-study precedent.

Tirzepatide has strong licensed dosing evidence. PP should present the FDA ladder prominently, then separately document slower or sub-label community practice rather than blending them into the approved schedule.